TheKi-67nuclearantigenisassociatedwithcellproliferationandfoundthroughoutthecellcycle;thoughnotinG0phase(1,2).TheassessmentofKi-67proliferationinbreastcancershasshowntheKi-67labellingindexisanimportantpredictorofsurvival(3).
MicroscopicevaluationofmitoticfiguresonH&Eisaroutineprocedureintheassessmentofthetumorgrades(4).However,thecountingofmitosisismanualandtimeconsumingwithassorteddifficultiesaswellasvariABIlitiesbetweeninterobserverassessments(5).HistoneH3phosphorylationatSerine10(pHH3)isinassociationwithmitoticchromatincondensationinlateG2andMphaseofthecellcycle.pHH3candistinguishmitosisfromapoptoticnuclei(6).TheimmunohistochemicalstainingofSerine10-pHH3hasbeenreportedtobecomparabletomitoticfiguresintheH&Esection(7-10).
Immunohistochemicalstudieshaveshownimmunostainingusinganti-Ki-67andanti-pHH3antibodiesprovidedimprovedpredictionofrecurrenceoftumorsandmaybecomeeffectiveancillarytoolsindecidingonoptimaltherapeuticmanagement(11).OtherstudieshaveshownKi-67andpHH3canbeusefulinseparatingmalignantmelanomafrombenignnevi(12).
Format | Predilute |
---|---|
Volume | 6.0ml |
IntendedUse | IVD |
ByLetter | K |
Clone | MIB-1BC37 |
Source | MouseMonoclonal,RabbitMonoclonal |
1.GerdesJ,etal.Cellcycleanalysisofacellproliferation-associatedhumannuclearantigendefinedbythemonoclonalantibodyKi-67.JImmunol.1984Oct;133(4):1710-5.
2.McCormickD,etal.DetectionoftheKi-67antigeninfixedandwaxembeddedsectionswiththemonoclonalantibodyMIB1.Histopathology.1993Apr;22(4):355-60.
3.PinderSE,etal.AssessmentofthenewproliferationMarkerMIB1inbreastcarcinomausingimageanalysis:associationswithotherprognosticfactorsandsurvival.BrJCancer.1995Jan;71(1):146-9.
4.JanninkI,etal.Comparisonoftheprognosticvalueoffourmethodstoassessmitoticactivityin186invasivebreastcancerpatients:classicalandrandommitoticactivityassessmentswithcorrectionforvolumepercentageofepithelium.HumPathol.1995Oct;26(10):1086-92.
5.YadavKS,etal.Assessmentofinterobservervariabilityinmitoticfigurecountingindifferenthistologicalgradesoforalsquamouscellcarcinoma.JContempDentPract.2012May1;13(3):339-44.
6.LadsteinRG,etal.PrognosticimportanceofthemitoticmarkerphosphohistoneH3incutaneousnodularmelanoma.JInvestDermatol.2012Apr;132(4):1247-52.
7.TharejaS,etal.Analysisoftumormitoticrateinthinmetastaticmelanomascomparedwiththinmelanomaswithoutmetastasisusingboththehematoxylinandeosinandantiphosphohistone3IHCstain.AmJDermatopathol.2014Jan;36(1):64-7.
8.IkenbergK,etal.Immunohistochemicaldualstainingasanadjunctinassessmentofmitoticactivityinmelanoma.JCutanPathol.2012Mar;39(3):324-30.
9.CasperDJ,etal.Useofanti-phosphohistoneH3immunohistochemistrytodeterminemitoticrateinthinmelanoma.AmJDermatopathol.2010Oct;32(7):650-4.
10.FultonR,MD,PhD,TachaD,PhD.UseofaNovelRabbitMonoclonalPhospho-HistoneH3(Ser10)versusH&EMitoticCountinMelanoma.USCAP2016,PosterSessionIV#96.
11.UguenA.etal.Immunostainingofphospho-histoneH3andKi-67improvesreproducibilityofrecurrenceriskassessmentofgastrointestinalstromaltumors.VirchowsArch.2015Jul;467(1):47-54.
12.NasrMR,El-Zammar.ComparisonofpHH3,Ki-67,andsurvivinimmunoreactivityinbenignandmalignantmelanocyticlesions.AmJDermatopathol.2008Apr;30(2):117-22.
13.CenterforDiseaseControlManual.Guide:SafetyManagement,NO.CDC-22,Atlanta,GA.April30,1976“DecontaminationofLaboratorySinkDrainstoRemoveAzideSalts.”
14.ClinicalandLaboratoryStandardsInstitute(CLSI).ProtectionofLaboratoryWorkersfromOccupationallyAcquiredInfections;ApprovedGuideline-FourthEditionCLSIdocumentM29-A4Wayne,PA2014.
Biocare医学教育外展计划通过Biocare仪器和试剂的技术教育为我们目前和潜在的客户提供支持。教育外展团队致力于通过教育指导,材料和计划使每个客户成功。我们将最新的科学发现纳入我们的培训中,提供新鲜,相关的内容。我们的目标是让受训人员以信心和专业知识来培训其同事,以掌握返回实验室所需的主题知识。
Biocare医学教育推广计划提供全面的培训,在我们的教育中心和培训实验室中使科学理论与实际实践学习保持平衡。小班授课和个性化的教学模块允许在高素质的技术专家的带领下定制课程。
在加利福尼亚州康科德市的生物保健医学教育中心和培训实验室接受培训
网络研讨会
大事记
Biocare Medical是国家组织技术培训协会的骄傲,提供NSH认可的课程。